2,541
Views
42
CrossRef citations to date
0
Altmetric
Brief Reports

Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate

ORCID Icon, , ORCID Icon, , , , ORCID Icon, , , , , , & show all
Pages 1262-1269 | Received 02 Nov 2016, Accepted 06 Mar 2017, Published online: 31 Oct 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Emma Davé, Oliver Durrant, Neha Dhami, Joanne Compson, Janice Broadbridge, Sophie Archer, Asher Maroof, Kevin Whale, Karelle Menochet, Pierre Bonnaillie, Emily Barry, Gavin Wild, Claude Peerboom, Pallavi Bhatta, Mark Ellis, Matthew Hinchliffe, David P. Humphreys & Sam P. Heywood. (2023) TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life. mAbs 15:1.
Read now

Articles from other publishers (41)

Maryam Ehsasatvatan & Bahram Baghban Kohnehrouz. (2023) Designing and computational analyzing of chimeric long-lasting GLP-1 receptor agonists for type 2 diabetes. Scientific Reports 13:1.
Crossref
Zhilong Shi, Fupeng Ren, Xiu Shen, Chaoying Zhang, Yingming Jin & Yiquan Cheng. (2023) Genetically Fused DARPins: A Novel Approach for Designing Extended-Release Thrombopoietin Mimetic Peptides. International Journal of Peptide Research and Therapeutics 29:5.
Crossref
Changzhen Zhang, Guosheng Gao, Yafeng Li, Jingjing Ying, Jianhui Li & Supei Hu. (2023) Design of a Dual Agonist of Exendin-4 and FGF21 as a Potential Treatment for Type 2 Diabetes Mellitus and Obesity. Iranian Journal of Pharmaceutical Research 22:1.
Crossref
Kenneth Kin-Wah To, Kwong-Sak Leung & William Chi-Shing Cho. (2023) MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing. Drugs and Drug Candidates 2:3, pages 591-623.
Crossref
Ilaria Saltarella, Concetta Altamura, Carmen Campanale, Paola Laghetti, Angelo Vacca, Maria Antonia Frassanito & Jean-François Desaphy. (2023) Anti-Angiogenic Activity of Drugs in Multiple Myeloma. Cancers 15:7, pages 1990.
Crossref
Vikas Chonira, Young D. Kwon, Jason Gorman, James Brett Case, Zhiqiang Ku, Rudo Simeon, Ryan G. Casner, Darcy R. Harris, Adam S. Olia, Tyler Stephens, Lawrence Shapiro, Michael F. Bender, Hannah Boyd, I-Ting Teng, Yaroslav Tsybovsky, Florian Krammer, Ningyan Zhang, Michael S. Diamond, Peter D. Kwong, Zhiqiang An & Zhilei Chen. (2022) A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins. Nature Chemical Biology 19:3, pages 284-291.
Crossref
Jinying Xia, Guosheng Gao, Changzhen Zhang, Jingjing Ying & Jianhui Li. (2023) Albumin-binding DARPins as scaffold improve the hypoglycemic and anti-obesity effects of exendin-4 in vivo. European Journal of Pharmaceutical Sciences, pages 106422.
Crossref
Sylvia Rothenberger, Daniel L. Hurdiss, Marcel Walser, Francesca Malvezzi, Jennifer Mayor, Sarah Ryter, Hector Moreno, Nicole Liechti, Andreas Bosshart, Chloé Iss, Valérie Calabro, Andreas Cornelius, Tanja Hospodarsch, Alexandra Neculcea, Thamar Looser, Anja Schlegel, Simon Fontaine, Denis Villemagne, Maria Paladino, Dieter Schiegg, Susanne Mangold, Christian Reichen, Filip Radom, Yvonne Kaufmann, Doris Schaible, Iris Schlegel, Christof Zitt, Gabriel Sigrist, Marcel Straumann, Julia Wolter, Marco Comby, Feyza Sacarcelik, Ieva Drulyte, Heyrhyoung Lyoo, Chunyan Wang, Wentao Li, Wenjuan Du, H. Kaspar Binz, Rachel Herrup, Sabrina Lusvarghi, Sabari Nath Neerukonda, Russell Vassell, Wei Wang, Julia M. Adler, Kathrin Eschke, Mariana Nascimento, Azza Abdelgawad, Achim D. Gruber, Judith Bushe, Olivia Kershaw, Charles G. Knutson, Kamal K. Balavenkatraman, Krishnan Ramanathan, Emanuel Wyler, Luiz Gustavo Teixeira Alves, Seth Lewis, Randall Watson, Micha A. Haeuptle, Alexander Zürcher, Keith M. Dawson, Daniel Steiner, Carol D. Weiss, Patrick Amstutz, Frank J. M. van Kuppeveld, Michael T. Stumpp, Berend-Jan Bosch, Olivier Engler & Jakob Trimpert. (2022) The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants. Nature Biotechnology 40:12, pages 1845-1854.
Crossref
Yu Zeng, Mengqiu Jiang, Sally Robinson, Zeyu Peng, Vikas Chonira, Rudo Simeon, Saul Tzipori, Junjie Zhang & Zhilei Chen. (2022) A Multi-Specific DARPin Potently Neutralizes Shiga Toxin 2 via Simultaneous Modulation of Both Toxin Subunits. Bioengineering 9:10, pages 511.
Crossref
L. McElwain, K. Phair, C. Kealey & D. Brady. (2022) Current trends in biopharmaceuticals production in Escherichia coli. Biotechnology Letters 44:8, pages 917-931.
Crossref
Huiyu Hu, Jeremy Quintana, Ralph Weissleder, Sareh Parangi & Miles Miller. (2022) Deciphering albumin-directed drug delivery by imaging. Advanced Drug Delivery Reviews 185, pages 114237.
Crossref
Lukas A. Rettenbacher, Klaudia Arauzo-Aguilera, Luisa Buscajoni, Angel Castillo-Corujo, Borja Ferrero-Bordera, Aliki Kostopoulou, Rafael Moran-Torres, David Núñez-Nepomuceno, Ayşegül Öktem, Arianna Palma, Beatrice Pisent, Martina Puricelli, Tobias Schilling, Aatir A. Tungekar, Jonathan Walgraeve, David Humphreys, Tobias von der Haar, Brigitte Gasser, Diethard Mattanovich, Lloyd Ruddock & Jan Maarten van Dijl. (2022) Microbial protein cell factories fight back?. Trends in Biotechnology 40:5, pages 576-590.
Crossref
Hanhee Cho, Seong Ik Jeon, Cheol-Hee Ahn, Man Kyu Shim & Kwangmeyung Kim. (2022) Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation. Pharmaceutics 14:4, pages 728.
Crossref
Johannes Schilling, Christian Jost, Ioana Mariuca Ilie, Joachim Schnabl, Oralea Buechi, Rohan S. Eapen, Rafaela Truffer, Amedeo Caflisch & Patrik Forrer. (2022) Thermostable designed ankyrin repeat proteins (DARPins) as building blocks for innovative drugs. Journal of Biological Chemistry 298:1, pages 101403.
Crossref
Aurélie Rondon, Sohaib Mahri, Francisco Morales‐Yanez, Mireille Dumoulin & Rita Vanbever. (2021) Protein Engineering Strategies for Improved Pharmacokinetics. Advanced Functional Materials 31:44.
Crossref
Charles Shin, Sung Soo Kim & Yong Hwa Jo. (2021) Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications. Molecular Therapy - Oncolytics 22, pages 166-179.
Crossref
Huanbo Tan, Wencheng Su, Wenyu Zhang, Jie Zhang, Michael Sattler & Peijian Zou. (2021) Generation of novel long-acting GLP-1R agonists using DARPins as a scaffold. International Journal of Pharmaceutics 607, pages 121043.
Crossref
Charlotte U. Zajc, Benjamin Salzer, Joseph M. Taft, Sai T. Reddy, Manfred Lehner & Michael W. Traxlmayr. (2020) Driving CARs with alternative navigation tools – the potential of engineered binding scaffolds. The FEBS Journal 288:7, pages 2103-2118.
Crossref
Rudo A Simeon, Yu Zeng, Vikas Chonira, Andrea Martinez Aguirre, Mauricio Lasagna, Marko Baloh, Joseph A Sorg, Cecilia Tommos & Zhilei Chen. (2021) Protease-stable DARPins as promising oral therapeutics. Protein Engineering, Design and Selection 34.
Crossref
Richard D. Baird, Constanza Linossi, Mark Middleton, Simon Lord, Adrian Harris, Jordi Rodón, Christof Zitt, Ulrike Fiedler, Keith M. Dawson, Nicolas Leupin, Michael T. Stumpp, Andreas Harstrick, Analía Azaro, Stefanie Fischer & Aurelius Omlin. (2021) First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology 39:2, pages 145-154.
Crossref
Colton J. Bracken, Shion A. Lim, Paige Solomon, Nicholas J. Rettko, Duy P. Nguyen, Beth Shoshana Zha, Kaitlin Schaefer, James R. Byrnes, Jie Zhou, Irene Lui, Jia Liu, Katarina Pance, Caleigh M. Azumaya, Julian R. Braxton, Axel F. Brilot, Meghna Gupta, Fei Li, Kyle E. Lopez, Arthur Melo, Gregory E. Merz, Frank Moss, Joana Paulino, Thomas H. PospiechJr.Jr., Sergei Pourmal, Cristina Puchades, Alexandrea N. Rizo, Amber M. Smith, Ming Sun, Paul V. Thomas, Feng Wang, Zanlin Yu, Daniel Asarnow, Julian R. Braxton, Melody G. Campbell, Cynthia M. Chio, Un Seng Chio, Miles Sasha Dickinson, Devan Diwanji, Bryan Faust, Meghna Gupta, Nick Hoppe, Mingliang Jin, Fei Li, Junrui Li, Yanxin Liu, Gregory E. Merz, Henry C. Nguyen, Joana Paulino, Thomas H. PospiechJr.Jr., Sergei Pourmal, Smriti Sangwan, Raphael Trenker, Donovan Trinidad, Eric Tse, Kaihua Zhang, Fengbo Zhou, Caleigh M. Azumaya, Christian Billesboelle, Alisa Bowen, Melody G. Campbell, Devan Diwanji, Nick Hoppe, Yen-Li Li, Phuong Nguyen, Carlos Nowotny, Cristina Puchades, Mali Safari, Smriti Sangwan, Kaitlin Schaefer, Amber M. Smith, Raphael Trenker, Tsz Kin Martin Tsui, Natalie Whitis, Jianhua Zhao, Daniel Asarnow, Caleigh M. Azumaya, Cynthia M. Chio, Bryan Faust, Meghna Gupta, Kate Kim, Michelle Moritz, Tristan W. Owens, Joana Paulino, Jessica K. Peters, Sergei Pourmal, Kaitlin Schaefer, Tsz Kin Martin Tsui, Justin Biel, Ishan Deshpande, Nadia Herrera, Huong T. Kratochvil, Xi Liu, Ursula Schulze-Gahmen, Iris D. Young, Jen Chen, Amy Diallo, Loan Doan, Sebastian Flores, Meghna Gupta, Mingliang Jin, Huong T. Kratochvil, Victor L. Lam, Yang Li, Megan Lo, Gregory E. Merz, Joana Paulino, Aye C. Thwin, Erron W. Titus, Zanlin Yu, Fengbo Zhou, Yang Zhang, David Bulkley, Arceli Joves, Almarie Joves, Liam McKay, Mariano Tabios, Eric Tse, David A. Agard, Yifan Cheng, James S. Fraser, Adam Frost, Natalia Jura, Tanja Kortemme, Nevan J. Krogan, Aashish Manglik, Oren S. Rosenberg, Daniel R. Southworth, Robert M. Stroud, Kliment A. Verba, Xin X. Zhou, Kevin K. Leung & James A. Wells. (2020) Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. Nature Chemical Biology 17:1, pages 113-121.
Crossref
Doreen Koenning & Jonas V. Schaefer. 2021. Introduction to Antibody Engineering. Introduction to Antibody Engineering 215 249 .
Guido Lancman, Joshua Richter & Ajai Chari. (2020) Bispecifics, trispecifics, and other novel immune treatments in myeloma. Hematology 2020:1, pages 264-271.
Crossref
Lucas Gutierrez, Nina S. Cauchon, Twinkle R. Christian, Michael J. Giffin & Michael J. Abernathy. (2020) The Confluence of Innovation in Therapeutics and Regulation: Recent CMC Considerations. Journal of Pharmaceutical Sciences 109:12, pages 3524-3534.
Crossref
Vajihe Akbari, C. Perry Chou & Daryoush Abedi. (2020) New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1874:2, pages 188448.
Crossref
Parastou Rahimizadeh, Sungtae Yang & Sung In Lim. (2020) Albumin: An Emerging Opportunity in Drug Delivery. Biotechnology and Bioprocess Engineering 25:6, pages 985-995.
Crossref
Federico Ricci, Francesco Bandello, Pierluigi Navarra, Giovanni Staurenghi, Michael Stumpp & Marco Zarbin. (2020) Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. International Journal of Molecular Sciences 21:21, pages 8242.
Crossref
Patrick L. Mulcrone, Shanique K. E. Edwards, Daniela N. Petrusca, Laura S. Haneline, Jesús Delgado-Calle & G. David Roodman. (2020) Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23. Scientific Reports 10:1.
Crossref
Ozgun Kilic, Marcos R. Matos de Souza, Abdulaziz A. Almotlak, Yiao Wang, Jill M. Siegfried, Mark D. Distefano & Carston R. Wagner. (2020) Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T Cell-Mediated Antitumor Responses and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression. Journal of Medicinal Chemistry 63:18, pages 10235-10245.
Crossref
Emelie Foord, Charlotte Klynning, Esther Schoutrop, Judith M. Förster, Jennifer Krieg, Anette Mörtberg, Mischa R. Müller, Christel Herzog, Dieter Schiegg, Denis Villemagne, Ulrike Fiedler, Dan Snell, Benjamin Kebble, Jonas Mattsson, Victor Levitsky & Michael Uhlin. (2020) Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins. Journal of Immunology Research 2020, pages 1-12.
Crossref
Michael T. Stumpp, Keith M. Dawson & H. Kaspar Binz. (2020) Beyond Antibodies: The DARPin® Drug Platform. BioDrugs 34:4, pages 423-433.
Crossref
Achille Patrizio Caputi & Pierluigi Navarra. (2020) Beyond antibodies: ankyrins and DARPins. From basic research to drug approval. Current Opinion in Pharmacology 51, pages 93-101.
Crossref
Michaela Gebauer & Arne Skerra. (2020) Engineered Protein Scaffolds as Next-Generation Therapeutics. Annual Review of Pharmacology and Toxicology 60:1, pages 391-415.
Crossref
Alessia Brossa, Lola Buono, Sofia Fallo, Alessandra Fiorio Pla, Luca Munaron & Benedetta Bussolati. (2019) Alternative Strategies to Inhibit Tumor Vascularization. International Journal of Molecular Sciences 20:24, pages 6180.
Crossref
Michaela Gebauer & Arne Skerra. (2019) Engineering of binding functions into proteins. Current Opinion in Biotechnology 60, pages 230-241.
Crossref
Zeyu Peng, Rudo Simeon, Samuel B. Mitchell, Junjie Zhang, Hanping Feng & Zhilei Chen. (2019) Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027. mSphere 4:5.
Crossref
Alexander W. Golinski, Patrick V. Holec, Katelynn M. Mischler & Benjamin J. Hackel. (2019) Biophysical Characterization Platform Informs Protein Scaffold Evolvability. ACS Combinatorial Science 21:4, pages 323-335.
Crossref
Huanbo Tan, Wencheng Su, Wenyu Zhang, Pengju Wang, Michael Sattler & Peijian Zou. (2019) Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins. Current Pharmaceutical Design 24:41, pages 4932-4946.
Crossref
Sophia Hober, Sarah Lindbo & Johan Nilvebrant. (2019) Bispecific applications of non-immunoglobulin scaffold binders. Methods 154, pages 143-152.
Crossref
Timothy Jenkins, Thomas Fryer, Rasmus Dehli, Jonas Jürgensen, Albert Fuglsang-Madsen, Sofie Føns & Andreas Laustsen. (2019) Toxin Neutralization Using Alternative Binding Proteins. Toxins 11:1, pages 53.
Crossref
Yu-wen Su & Wei Wang. (2018) Surface plasmon resonance sensing: from purified biomolecules to intact cells. Analytical and Bioanalytical Chemistry 410:17, pages 3943-3951.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.